Targeting BRAF for patients with melanoma

被引：101

作者：

Arkenau, H-T ^{[1
]}

Kefford, R. ^{[2
,3
]}

Long, G. V. ^{[2
,3
]}

机构：

[1] Sarah Cannon Res UK, London W1G 6AD, England

[2] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia

[3] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2006, Australia

来源：

BRITISH JOURNAL OF CANCER | 2011年 / 104卷 / 03期

关键词：

BRAF; BRAF(V600E); melanoma; PI3K-AKT-mTOR; RAS-RAF-MEK-ERK; HISTONE DEACETYLASE INHIBITOR; B-RAF; PHASE-II; MUTATIONS; PATHWAY; CELLS; RESISTANCE; COMBINATION; SORAFENIB; COOPERATE;

D O I：

10.1038/sj.bjc.6606030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. The majority of patients on early trials of these drugs develop secondary resistance and subsequent disease progression and it is, therefore, critical to understand the underlying escape mechanisms leading to resistance. British Journal of Cancer (2011) 104, 392-398. doi:10.1038/sj.bjc.6606030 www.bjcancer.com Published online 7 December 2010 (C) 2011 Cancer Research UK

引用

页码：392 / 398

页数：7

共 48 条

[1] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].

Balch, CM ;

Soong, SJ ;

Gershenwald, JE ;

Thompson, JF ;

Reintgen, DS ;

Cascinelli, N ;

Urist, M ;

McMasters, KM ;

Ross, MI ;

Kirkwood, JM ;

Atkins, MB ;

Thompson, JA ;

Coit, DG ;

Byrd, D ;

Desmond, R ;

Zhang, YT ;

Liu, PY ;

Lyman, GH ;

Morabito, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634

[2] Heat Shock Protein 90 as a Drug Target: Some Like It Hot [J].

Banerji, Udai .

CLINICAL CANCER RESEARCH, 2009, 15 (01) :9-14

[3]

BEDOGNI B, 2005, MOL CANCER THER, V5, P1136

[4] Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway [J].

Calipel, A ;

Lefevre, G ;

Pouponnot, C ;

Mouriaux, F ;

Eychène, A ;

Mascarelli, F .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) :42409-42418

[5] Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 [J].

Chapman, P. ;

Puzanov, I. ;

Sosman, J. ;

Kim, K. ;

Ribas, A. ;

McArthur, G. ;

Lee, R. ;

Grippo, J. ;

Nolop, K. ;

Flaherty, K. .

EJC SUPPLEMENTS, 2009, 7 (03) :5-5

[6] Akt and mutant V600EB-Raf cooperate to promote early melanoma development [J].

Cheung, Mitchefl ;

Sharma, Arati ;

Madhunapantula, SubbaRao V. ;

Robertson, Gavin P. .

CANCER RESEARCH, 2008, 68 (09) :3429-3439

[7]

Cho DC, 2009, J CLIN ONCOL, V27

[8]

COSMIC, Catalog of Somatic Mutations in Cancer

[9] Distinct sets of genetic alterations in melanoma [J].

Curtin, JA ;

Fridlyand, J ;

Kageshita, T ;

Patel, HN ;

Busam, KJ ;

Kutzner, H ;

Cho, KH ;

Aiba, S ;

Bröcker, EB ;

LeBoit, PE ;

Pinkel, D ;

Bastian, BC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147

[10] BrafV600E cooperates with Pten loss to induce metastatic melanoma [J].

Dankort, David ;

Curley, David P. ;

Cartlidge, Robert A. ;

Nelson, Betsy ;

Karnezis, Anthony N. ;

Damsky, William E., Jr. ;

You, Mingjian J. ;

DePinho, Ronald A. ;

McMahon, Martin ;

Bosenberg, Marcus .

NATURE GENETICS, 2009, 41 (05) :544-552

← 1 2 3 4 5 →